Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and/or more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer.

Study Overview

• Status: Recruiting
• Conditions: Stage III Pancreatic Cancer AJCC v8; Locally Advanced Pancreatic Adenocarcinoma
• Intervention / Treatment: Procedure: Magnetic Resonance Imaging; Procedure: Computed Tomography; Procedure: Biospecimen Collection; Other: Placebo Administration; Drug: Peposertib; Radiation: Hypofractionated Radiation Therapy; Procedure: Biopsy Procedure

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of M3814 (peposertib) in combination with hypofractionated radiotherapy in patients receiving treatment for locally advanced pancreatic adenocarcinoma (LAPC). (Phase I) II. To determine the difference in progression free survival (PFS) between patients with LAPC treated with hypofractionated radiotherapy in combination with M3814 (peposertib) as compared to patients treated with hypofractionated radiotherapy alone. (Phase II)

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. (Phase I) II. To evaluate plasma pharmacokinetic (PK) profiles of M3814 (peposertib) in patients receiving hypofractionated radiotherapy. (Phase I) III. To compare the 2-year overall survival (OS) rate of patients treated with hypofractionated radiotherapy plus M3814 (peposertib) to that of those treated with hypofractionated radiotherapy alone. (Phase II) IV. To compare the objective response rate (ORR) by imaging of patients treated with hypofractionated radiotherapy plus M3814 (peposertib) to that of those treated with hypofractionated radiotherapy alone. (Phase II) V. To compare the disease control rate in patients treated with hypofractionated radiotherapy plus M3814 (peposertib) as compared to those patients treated with hypofractionated radiotherapy alone. (Phase II) VI. To explore gene signature patterns in baseline patient tumor tissues that may suggest response to the combination of M3814 (peposertib) and radiotherapy, as identified on whole exome sequencing and ribonucleic acid (RNA) sequencing (seq). (Phase II)

EXPLORATORY OBJECTIVE:

I. To explore changes in gene signature induced by M3814 (peposertib) and hypofractionated radiotherapy treatment as identified in analysis of cell-free deoxyribonucleic acid (DNA) from the peripheral blood. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of M3814 followed by a phase II study.

PHASE I: Patients undergo hypofractionated radiation therapy for 5 fractions every other day (QOD) over 2 weeks and receive M3814 orally (PO) once daily (QD) for 14 days in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 groups.

GROUP I: Patients undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity.

GROUP II: Patients undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo computed tomography (CT) and magnetic resonance imaging (MRI) during screening and on study.

After completion of study treatment, patients are followed up at 30, 60, and 90 days, and then every 3 months for up to 2 years.

• Study Type: Interventional
• Enrollment (Estimated): 92
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Duarte, California, United States, 91010
      • Recruiting
      • City of Hope Comprehensive Cancer Center
      • Contact: Site Public Contact; Phone Number: 800-826-4673; Email: becomingapatient@coh.org
      • Principal Investigator: Vincent Chung
    • Irvine, California, United States, 92618
      • Recruiting
      • City of Hope at Irvine Lennar
      • Contact: Site Public Contact; Phone Number: 877-467-3411
      • Principal Investigator: Vincent Chung
    • Irvine, California, United States, 92612
      • Recruiting
      • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Contact: Site Public Contact; Phone Number: 877-827-8839; Email: ucstudy@uci.edu
      • Principal Investigator: Farshid Dayyani
    • Orange, California, United States, 92868
      • Recruiting
      • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Contact: Site Public Contact; Phone Number: 877-827-8839; Email: ucstudy@uci.edu
      • Principal Investigator: Farshid Dayyani
    • Sacramento, California, United States, 95817
      • Recruiting
      • University of California Davis Comprehensive Cancer Center
      • Contact: Site Public Contact; Phone Number: 916-734-3089
      • Principal Investigator: Edward J. Kim
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Recruiting
      • UCHealth University of Colorado Hospital
      • Contact: Site Public Contact; Phone Number: 720-848-0650
      • Principal Investigator: Sarah L. Davis
  • District of Columbia
    • Washington D.C., District of Columbia, United States, 20016
      • Recruiting
      • Sibley Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 202-243-2373; Email: jquiver1@jhmi.edu
      • Principal Investigator: Michael J. Pishvaian
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Active, not recruiting
      • Northwestern University
  • Kansas
    • Fairway, Kansas, United States, 66205
      • Recruiting
      • University of Kansas Clinical Research Center
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Hays, Kansas, United States, 67601
      • Recruiting
      • HaysMed
      • Contact: Site Public Contact; Phone Number: 785-623-5774
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Kansas City, Kansas, United States, 66160
      • Recruiting
      • University of Kansas Cancer Center
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Lawrence, Kansas, United States, 66044
      • Recruiting
      • Lawrence Memorial Hospital
      • Contact: Site Public Contact; Phone Number: 785-505-2800; Email: Stephanie.Norris@LMH.ORG
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Olathe, Kansas, United States, 66061
      • Recruiting
      • The University of Kansas Cancer Center - Olathe
      • Principal Investigator: Anup K. Kasi Loknath Kumar
      • Contact: Site Public Contact; Phone Number: 913-588-1569; Email: OlatheCCResearch@kumc.edu
    • Overland Park, Kansas, United States, 66210
      • Recruiting
      • University of Kansas Cancer Center-Overland Park
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Pittsburg, Kansas, United States, 66762
      • Suspended
      • Mercy Hospital Pittsburg
    • Salina, Kansas, United States, 67401
      • Recruiting
      • Salina Regional Health Center
      • Contact: Site Public Contact; Phone Number: 785-452-7038; Email: mleepers@srhc.com
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Topeka, Kansas, United States, 66606
      • Recruiting
      • University of Kansas Health System Saint Francis Campus
      • Contact: Site Public Contact; Phone Number: 785-295-8000
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Westwood, Kansas, United States, 66205
      • Recruiting
      • University of Kansas Hospital-Westwood Cancer Center
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Anup K. Kasi Loknath Kumar
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • Withdrawn
      • University of Kentucky/Markey Cancer Center
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Active, not recruiting
      • Wayne State University/Karmanos Cancer Institute
    • Farmington Hills, Michigan, United States, 48334
      • Active, not recruiting
      • Weisberg Cancer Treatment Center
  • Missouri
    • Kansas City, Missouri, United States, 64154
      • Recruiting
      • University of Kansas Cancer Center - North
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Kansas City, Missouri, United States, 64108
      • Recruiting
      • University Health Truman Medical Center
      • Contact: Site Public Contact; Phone Number: 816-404-4375
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • Lee's Summit, Missouri, United States, 64064
      • Recruiting
      • University of Kansas Cancer Center - Lee's Summit
      • Contact: Site Public Contact; Phone Number: 913-588-3671; Email: KUCC_Navigation@kumc.edu
      • Principal Investigator: Anup K. Kasi Loknath Kumar
    • North Kansas City, Missouri, United States, 64116
      • Suspended
      • University of Kansas Cancer Center at North Kansas City Hospital
  • New Hampshire
    • Lebanon, New Hampshire, United States, 03756
      • Active, not recruiting
      • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
  • New Jersey
    • Livingston, New Jersey, United States, 07039
      • Recruiting
      • Saint Barnabas Medical Center
      • Principal Investigator: Matthew P. Deek
      • Contact: Site Public Contact; Phone Number: 973-322-2934; Email: joanne.loeb@rwjbh.org
    • Long Branch, New Jersey, United States, 07740
      • Recruiting
      • Monmouth Medical Center
      • Principal Investigator: Matthew P. Deek
      • Contact: Site Public Contact; Phone Number: 732-923-6564; Email: mary.danish@rwjbh.org
    • New Brunswick, New Jersey, United States, 08903
      • Recruiting
      • Rutgers Cancer Institute of New Jersey
      • Principal Investigator: Matthew P. Deek
      • Contact: Site Public Contact; Phone Number: 732-235-7356
  • New York
    • Buffalo, New York, United States, 14263
      • Active, not recruiting
      • Roswell Park Cancer Institute
    • New York, New York, United States, 10029
      • Recruiting
      • Mount Sinai Hospital
      • Contact: Site Public Contact; Phone Number: 212-824-7309; Email: CCTO@mssm.edu
      • Principal Investigator: Karyn A. Goodman
    • New York, New York, United States, 10065
      • Recruiting
      • NYP/Weill Cornell Medical Center
      • Principal Investigator: Allyson J. Ocean
      • Contact: Site Public Contact; Phone Number: 212-746-1848
    • New York, New York, United States, 10016
      • Active, not recruiting
      • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    • The Bronx, New York, United States, 10461
      • Active, not recruiting
      • Montefiore Medical Center-Einstein Campus
    • The Bronx, New York, United States, 10467
      • Active, not recruiting
      • Montefiore Medical Center - Moses Campus
  • North Carolina
    • Clemmons, North Carolina, United States, 27012
      • Active, not recruiting
      • Wake Forest University at Clemmons
    • Wilkesboro, North Carolina, United States, 28659
      • Active, not recruiting
      • Wake Forest Baptist Health - Wilkes Medical Center
    • Winston-Salem, North Carolina, United States, 27157
      • Active, not recruiting
      • Wake Forest University Health Sciences
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15232
      • Recruiting
      • University of Pittsburgh Cancer Institute (UPCI)
      • Contact: Site Public Contact; Phone Number: 412-647-8073
      • Principal Investigator: Janie Y. Zhang
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Recruiting
      • Vanderbilt University/Ingram Cancer Center
      • Contact: Site Public Contact; Phone Number: 800-811-8480
      • Principal Investigator: Dana B. Cardin
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • Active, not recruiting
      • Huntsman Cancer Institute/University of Utah
  • Virginia
    • Richmond, Virginia, United States, 23298
      • Recruiting
      • VCU Massey Comprehensive Cancer Center
      • Principal Investigator: Emma C. Fields
      • Contact: Site Public Contact; Phone Number: 804-628-6430; Email: CTOclinops@vcu.edu
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • Recruiting
      • University of Wisconsin Carbone Cancer Center - University Hospital
      • Principal Investigator: Monica A. Patel
      • Contact: Site Public Contact; Phone Number: 800-622-8922; Email: clinicaltrials@cancer.wisc.edu
    • Madison, Wisconsin, United States, 53718
      • Recruiting
      • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
      • Principal Investigator: Monica A. Patel
      • Contact: Site Public Contact; Phone Number: 800-622-8922; Email: clinicaltrials@cancer.wisc.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients must have pathologically confirmed pancreatic adenocarcinoma. Patients with alternative or mixed histologies (i.e., squamous, neuroendocrine, acinar, colloid) are not eligible
• Received 4-6 months of induction chemotherapy with fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX), fluorouracil, liposomal irinotecan, leucovorin, oxaliplatin (NALIRIFOX), or gemcitabine/Abraxane, as per standard of care

• Patients must have locally advanced pancreatic cancer according to National Comprehensive Cancer Network (NCCN) Guidelines (version 1.2020) on pancreas protocol CT scan performed within 21 days of registration. Locally advanced disease is defined as any of the following:

  • For head or uncinate process tumors:

    • Solid tumor contact with superior mesenteric artery > 180 degrees
    • Solid tumor contact with the celiac axis > 180 degrees
    • Solid tumor contact with the common or proper hepatic arteries > 180 degrees or

  • For pancreatic body or tail tumors:

    • Solid tumor contact of > 180 degrees with the superior mesenteric artery or celiac axis
    • Solid tumor contact with the celiac axis and aortic involvement or
  • Unreconstructible superior mesenteric vein or portal vein due to tumor involvement or occlusion (can be due to tumor or bland thrombus)
• The determination of locally advanced pancreatic cancer and plan for non-operative treatment on this clinical trial must be confirmed through local multi-disciplinary review
• Measurable disease per response evaluation criteria in solid tumors (RECIST) version (v)1.1
• Age >= 18 years. Because no dosing or adverse event data are currently available on the use of M3814 (peposertib) in combination with hypofractionated radiation in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
• Leukocytes >= 4,000/mcL
• Absolute neutrophil count >= 1.5 x 10^9/L.
• Hemoglobin >= 9 g/dL
• Platelets >= 100 x 10^9/L
• Total bilirubin =< 2.0 x institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional ULN
• Creatinine =< 1.5 x institutional ULN
• Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2
• Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
• For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
• Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

• Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female patients of childbearing potential and male patients must be willing to use an adequate method of contraception for the course of the study through 12 weeks after the last dose of study medication.

  • Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
• Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function. To be eligible for this trial, patients should be American Heart Association Stage B (people without current or previous symptoms of heart failure but with either structural heart disease, increased filling pressures in the heart or other risk factors) or better and New York Heart Association Functional Classification II (slight limitation of physical activity, comfortable at rest, ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain), or better
• Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

• Patients who have completed induction chemotherapy less than 2 weeks or more than 8 weeks prior to study enrollment
• Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy grade =< 2
• Patients who are receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to M3814 (peposertib)
• Evidence of distant metastatic disease
• More than 1 line of chemotherapy for the treatment of localized pancreatic cancer, unless the change in treatment was made only for toxicity
• Prior abdominal radiation
• Active inflammatory bowel disease or connective tissue disease
• Inability to swallow oral medications or gastrointestinal disease limiting absorption of oral agents
• History of anaphylactic reaction to iodinated intravenous (IV) contrast required for radiation simulation. Patients with mild reactions may be enrolled, but must receive premedications for contrast allergy prior to imaging

• Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9, and CYP2C19. Concomitant use of substrates with a narrow therapeutic index that are metabolized by CYP1A2, CYP2B6, CYP2C8, and CYP3A4/5 are also excluded.

  • Use caution with other substrates of CYP3A4/5, CYP1A2, CYP2B6, CYP2C8 and substrates of P-gp, BCRP, OCT1, OAT3, OATP1B1, OATP1B3, MATE1, and MATE-2K with a narrow therapeutic index. Close monitoring is advised.

Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. (Patient Drug Interactions Handout and Wallet Card) should be provided to patients

• Patients who cannot discontinue concomitant proton-pump inhibitors (PPIs). Patients may confer with the study doctor to determine if such medications can be discontinued. These must be discontinued >= 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate. H2 blockers and antacids are allowed.
• Patients who have received a live attenuated vaccine within 30 days of dosing with M3814 (peposertib)
• Patients with uncontrolled intercurrent illness
• Patients with psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study because M3814 (peposertib) is a DNA-protein kinase (PK) inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M3814 (peposertib), breastfeeding should be discontinued if the mother is treated with M3814 (peposertib)
• Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Phase II Group II(hypofractionated radiation therapy, placebo); Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.	Procedure: Magnetic Resonance Imaging; Undergo MRI; Other Names: MRI; Magnetic Resonance; Magnetic Resonance Imaging Scan; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; MR; MR Imaging; MRI Scan; NMR Imaging; NMRI; Nuclear Magnetic Resonance Imaging; Magnetic Resonance Imaging (MRI); sMRI; Magnetic resonance imaging (procedure); MRIs; Structural MRI; Procedure: Computed Tomography; Undergo CT; Other Names: CT; CAT; CAT Scan; Computed Axial Tomography; Computerized Axial Tomography; Computerized Tomography; CT Scan; tomography; Computerized axial tomography (procedure); Computerized Tomography (CT) scan; Diagnostic CAT Scan; Diagnostic CAT Scan Service Type; Procedure: Biospecimen Collection; Undergo blood sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Sample Collection; Other: Placebo Administration; Given PO; Radiation: Hypofractionated Radiation Therapy; Undergo hypofractionated radiation therapy; Other Names: Hypofractionated Radiotherapy; hypofractionation; Radiation, Hypofractionated; Hypofractionated; Procedure: Biopsy Procedure; Undergo tissue collection; Other Names: Bx; BIOPSY_TYPE; Biopsy
Experimental: Phase I (hypofractionated radiation therapy, M3814); Patients in Phase I undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.	Procedure: Magnetic Resonance Imaging; Undergo MRI; Other Names: MRI; Magnetic Resonance; Magnetic Resonance Imaging Scan; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; MR; MR Imaging; MRI Scan; NMR Imaging; NMRI; Nuclear Magnetic Resonance Imaging; Magnetic Resonance Imaging (MRI); sMRI; Magnetic resonance imaging (procedure); MRIs; Structural MRI; Procedure: Computed Tomography; Undergo CT; Other Names: CT; CAT; CAT Scan; Computed Axial Tomography; Computerized Axial Tomography; Computerized Tomography; CT Scan; tomography; Computerized axial tomography (procedure); Computerized Tomography (CT) scan; Diagnostic CAT Scan; Diagnostic CAT Scan Service Type; Procedure: Biospecimen Collection; Undergo blood sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Sample Collection; Drug: Peposertib; Given PO; Other Names: MSC2490484A; 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-; M 3814; M-3814; M3814; MSC 2490484A; MSC-2490484A; Nedisertib; Radiation: Hypofractionated Radiation Therapy; Undergo hypofractionated radiation therapy; Other Names: Hypofractionated Radiotherapy; hypofractionation; Radiation, Hypofractionated; Hypofractionated; Procedure: Biopsy Procedure; Undergo tissue collection; Other Names: Bx; BIOPSY_TYPE; Biopsy
Experimental: Phase II Group I (hypofractionated radiation therapy M3814); Patients in Phase II undergo hypofractionated radiation therapy for 5 fractions QOD over 2 weeks and receive M3814 PO QD for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection and tissue biopsy on study. Patients also undergo CT and MRI during screening and on study.	Procedure: Magnetic Resonance Imaging; Undergo MRI; Other Names: MRI; Magnetic Resonance; Magnetic Resonance Imaging Scan; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; MR; MR Imaging; MRI Scan; NMR Imaging; NMRI; Nuclear Magnetic Resonance Imaging; Magnetic Resonance Imaging (MRI); sMRI; Magnetic resonance imaging (procedure); MRIs; Structural MRI; Procedure: Computed Tomography; Undergo CT; Other Names: CT; CAT; CAT Scan; Computed Axial Tomography; Computerized Axial Tomography; Computerized Tomography; CT Scan; tomography; Computerized axial tomography (procedure); Computerized Tomography (CT) scan; Diagnostic CAT Scan; Diagnostic CAT Scan Service Type; Procedure: Biospecimen Collection; Undergo blood sample collection; Other Names: Biological Sample Collection; Biospecimen Collected; Specimen Collection; Sample Collection; Drug: Peposertib; Given PO; Other Names: MSC2490484A; 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-; M 3814; M-3814; M3814; MSC 2490484A; MSC-2490484A; Nedisertib; Radiation: Hypofractionated Radiation Therapy; Undergo hypofractionated radiation therapy; Other Names: Hypofractionated Radiotherapy; hypofractionation; Radiation, Hypofractionated; Hypofractionated; Procedure: Biopsy Procedure; Undergo tissue collection; Other Names: Bx; BIOPSY_TYPE; Biopsy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (Phase I)		Up to 14 days
Recommended phase 2 dose (Phase I)		Up to 14 days
Progression-free survival rate (Phase II)	The 95% confidence intervals will be provided.	Time from randomization to progression or death whichever occurs first, assessed up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	Will be analyzed using a log-rank test to test for differences between the treatment groups in survival experience. The proportion of patients who survive through 2 years (i.e. the 2-year OS rate) will be compared between arms using Kaplan-Meier estimates.	Time between the date of randomization and the date of patient death, assessed up to 2 years
Two-year OS	Defined as the rate of patient survival at 2 years following completion of study treatment (based on Kaplan-Meier method).	At 2 years
Overall response rate	Defined as the rate of complete or partial response by imaging following study treatment as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Will be summarized and compared between arms.	Up to 2 years
Disease control rate	Defined as rate of stable disease, complete or partial response by imaging as assessed by RECIST v1.1. Will be summarized and compared between arms.	Up to 2 years
Pharmacokinetic markers of M3814	M3814 concentration time data will be analyzed non-compartmentally and reported descriptively.	Up to 2 years
Gene signature of tumor	Defined according to whole exome sequencing and ribonucleic acid sequencing, with a focus on deoxyribonucleic acid (DNA) damage repair signatures. Will be reported descriptively.	Up to 2 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gene signature of cell-free DNA from peripheral blood	Results of cell-free DNA analysis will be compared pre- and post-treatment and reported descriptively.	Baseline and after treatment

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Sarah L Davis, JHU Sidney Kimmel Comprehensive Cancer Center LAO

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2021
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026

Study Registration Dates

• First Submitted: November 20, 2019
• First Submitted That Met QC Criteria: November 20, 2019
• First Posted (Actual): November 21, 2019

Study Record Updates

• Last Update Posted (Actual): June 2, 2026
• Last Update Submitted That Met QC Criteria: May 30, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Neoplasms by Site; Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Investigative Techniques; Therapeutics; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Surgical Procedures, Operative; Cytological Techniques; Cytodiagnosis; Physical Phenomena; Diagnostic Techniques, Surgical; Chemistry Techniques, Analytical; Spectrum Analysis; Radiotherapy; Dose Fractionation, Radiation; Radiotherapy Dosage; Radiation; Biopsy; Specimen Handling; Magnetic Resonance Spectroscopy; Radiation Dose Hypofractionation; peposertib
• Other Study ID Numbers: NCI-2019-07645 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); UM1CA186691 (U.S. NIH Grant/Contract); 10366 (Other Identifier: CTEP)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No